pervanadate has been researched along with Cell-Transformation--Neoplastic* in 2 studies
2 other study(ies) available for pervanadate and Cell-Transformation--Neoplastic
Article | Year |
---|---|
Rac1 function is required for Src-induced transformation. Evidence of a role for Tiam1 and Vav2 in Rac activation by Src.
The proto-oncogene c-Src has been implicated in the development and progression of a number of human cancers including those of colon and breast. Accumulating evidence indicates that activated alleles of Src may induce cell transformation through Ras-ERK-dependent and -independent pathways. Here we show that Rac1 activity is strongly elevated in Src-transformed cells and that this small G protein is a critical component of the pathway connecting oncogenic Src with cell transformation. We further show that Vav2 and the ubiquitously expressed Rac1 guanine nucleotide exchange factor Tiam1 are phosphorylated in tyrosine residues in cells transfected with active and oncogenic Src. Moreover, phosphorylation of Tiam1 in cells treated with pervanadate, a potent inhibitor of tyrosine phosphatases, was partially inhibited by the Src inhibitor SU6656. Using truncated mutants of Tiam1, we demonstrate that multiple sites can be tyrosine-phosphorylated by Src. Furthermore, Tiam1 cooperated with Src to induce activation of Rac1 in vivo and the formation of membrane ruffles. Similarly, activation of JNK and the c-jun promoter by Src were also potently increased by Tiam1. Together, these results suggest that Vav2 and Tiam1 may act as downstream effectors of Src, thereby regulating Rac1-dependent pathways that participate in Src-induced cell transformation. Topics: 3T3 Cells; Alleles; Animals; Binding Sites; Catalysis; Cell Line; Cell Transformation, Neoplastic; DNA; Enzyme Activation; Enzyme Inhibitors; Genes, Reporter; GTP Phosphohydrolases; Guanine Nucleotide Exchange Factors; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mice; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Mutation; Oncogene Proteins; Phosphorylation; Plasmids; Promoter Regions, Genetic; Proteins; Proto-Oncogene Mas; Proto-Oncogene Proteins c-jun; Proto-Oncogene Proteins c-vav; Proto-Oncogene Proteins pp60(c-src); rac1 GTP-Binding Protein; Sulfonamides; T-Lymphoma Invasion and Metastasis-inducing Protein 1; Time Factors; Transfection; Tyrosine; Vanadates | 2003 |
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.
The BCR/ABL oncogene causes chronic myelogenous leukemia, a myeloproliferative disorder characterized by clonal expansion of hematopoietic progenitor cells and myeloid cells. It is shown here that transformation of the hematopoietic cell lines Ba/F3, 32Dcl3, and MO7e with BCR/ABL results in an increase in reactive oxygen species (ROS) compared with quiescent, untransformed cells. The increase in ROS was directly due to BCR/ABL because it was blocked by the ABL-specific tyrosine kinase inhibitor STI571. Oxidative stress through ROS is believed to have many biochemical effects, including the potential ability to inhibit protein-tyrosine phosphatases (PTPases). To understand the significance of increased production of ROS, a model system was established in which hydrogen peroxide (H(2)O(2)) was added to untransformed cells to mimic the increase in ROS induced constitutively by BCR/ABL. H(2)O(2) substantially reduced total cellular PTPase activity to a degree approximately equivalent to that of pervanadate, a well known PTPase inhibitor. Further, stimulation of untransformed cells with H(2)O(2) or pervanadate increased tyrosine phosphorylation of each of the most prominent known substrates of BCR/ABL, including c-ABL, c-CBL, SHC, and SHP-2. Treatment of the BCR/ABL-expressing cell line MO7/p210 with the reducing agents pyrrolidine dithiocarbamate or N-acetylcysteine reduced the accumulation of ROS and also decreased tyrosine phosphorylation of cellular proteins. Further, treatment of MO7e cells with H(2)O(2) or pervanadate increased the tyrosine kinase activity of c-ABL. Drugs that alter ROS metabolism or reactivate PTPases may antagonize BCR/ABL transformation. Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydrogen Peroxide; Megakaryocytes; Mice; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Reactive Oxygen Species; Rotenone; Signal Transduction; Vanadates | 2000 |